Loading...
NPI 1225413099 · Valdosta, GA · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
South Georgia Toxicology, Inc is a clinical medical laboratory provider located in Valdosta, Georgia. This profile covers 5 Medicare and 43 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | South Georgia Toxicology, Inc |
| Address | 3312 N Oak Street Ext |
| City | Valdosta |
| State | GA |
| ZIP | 31605 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | July 22, 2015 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicaid | $2.8M |
| Medicare | $2.2M |
Service-line profile: SOUTH GEORGIA TOXICOLOGY operates as a high-volume clinical toxicology laboratory focused on multi-drug definitive panels and routine presumptive screens. Its Medicare and Medicaid top codes are dominated by definitive multi-class confirmations (G0483, G0482, G0481) and instrumented presumptive screening (80307), and the G0483 description specifically includes specimen validity testing and large-panel (22+ drug class) analysis, which signals a lab setup oriented toward comprehensive confirmatory testing rather than only point-of-care immunoassays.
Revenue concentration by code: This provider’s Medicare revenue is highly concentrated, with the precomputed top 3 Medicare codes accounting for 97.8% of total Medicare revenue, and its Medicaid revenue is similarly concentrated with the precomputed top 3 Medicaid codes accounting for 87.5% of total Medicaid revenue. That degree of concentration indicates most reimbursement is driven by a very small set of high-complexity toxicology services rather than a broad mix of low-value tests.
Payer mix and scale: SOUTH GEORGIA TOXICOLOGY reports $2.2M in lifetime Medicare revenue and $2.8M in lifetime Medicaid revenue, so Medicaid represents the slightly larger single-payer source on file while the practice is not effectively single-payer. Both payers contribute material revenue, making the provider sensitive to reimbursement changes across both Medicare and Medicaid.
Medicare competitive standing: On Medicare claims the provider is a national high-volume performer for its flagship services — G0483 generated $1.5M and ranks #14 of 1063 nationally (99th percentile; notably above typical national volume for this code), and 80307 generated $384.1K and ranks #34 of 4760 nationally (99th percentile; notably above typical national volume for this code). These rankings indicate the lab is among the largest national billers for multi-class definitive testing and high-volume presumptive screening.
Medicaid competitive standing and breadth: In Medicaid the provider’s activity is concentrated in G0483 ($2.1M, 75.8% of Medicaid revenue) where it ranks #5 of 29 in-state (86th percentile; typical, unremarkable volume for this code), but it also shows state-leading volume on some niche analyte codes — notably 80371 ranks #1 of 9 in-state (100th percentile; notably above typical state volume for this code). Additionally, numerous single-analyte Medicaid codes (for example 80356 $23.1K, rank #2 of 14; 83992 $15K, rank #2 of 14) show top-quartile or higher in-state performance, suggesting the lab offers a broad menu of specific assays used frequently by Medicaid.
Operational implications of unit mix: The Medicaid code mix shows very large claim counts with low per-claim payments (for example 80307: 12.3K claims at $12 avg paid/claim producing $147.6K), whereas Medicare revenues are driven by fewer, higher-paid definitive panels (for example G0483: 6.3K claims at $242 avg paid/claim producing $1.5M). This combination implies the provider sustains volume operations (many low-dollar screening claims) alongside higher-margin confirmatory testing workflows, requiring both high-throughput instrumentation and capabilities for advanced confirmatory methodologies (GC/MS, LC/MS).
Tenure and stability: The provider’s NPI was enumerated on 2015-07-22 (~11 years ago), indicating roughly a decade of billing history under this identifier. Combined with sustained high national rankings on select Medicare codes and concentrated Medicaid volume, the tenure supports a picture of an established regional toxicology lab rather than a new entrant.
Concentration risk and contracting sensitivity: Given that the top three Medicare codes account for 97.8% of Medicare revenue and the top three Medicaid codes account for 87.5% of Medicaid revenue, any payer policy, reimbursement rate change, or credentialing shift affecting those specific codes (notably G0483, G0482, G0481, and 80307) could materially alter the provider’s revenue profile. Analysts and contracting teams should therefore prioritize evaluation and negotiation around those high-impact codes when assessing financial risk or partnership opportunities.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
5 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 6,330 | $240 | $1.5M |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 6,300 | $60 | $384.1K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 1,220 | $200 | $237.9K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 280 | $150 | $42.1K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 60 | $110 | $7.1K |
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 5 CPT/HCPCS codes.
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
43 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 17,020 | $120 | $2.1M |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 2,240 | $80 | $174.5K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 12,300 | $10 | $147.6K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 1,090 | $50 | $56.5K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 2,520 | $20 | $40.4K |
| 80356 | The lab analyst measures the amount of or detects the presence of heroin metabolite in the patient specimen. | 5,770 | $1 | $23.1K |
| 83992 | The lab analyst measures the level of this drug, phencyclidine, typically in a urine or blood sample. This very potent street drug is a common drug of abuse. | 5,010 | $1 | $15K |
| 80321 | The lab analyst detects and measures the alcohol biomarker in a patient specimen. Alcohol biomarkers are physiological indicators of the alcohol exposure or ingestion. In this test, the analyst tests… | 3,400 | $1 | $13.6K |
| 80366 | The lab analyst measures the amount of or detects the presence of pregabalin, a drug that treats nerve pain and seizures, in a patient specimen. | 4,400 | $1 | $13.2K |
| 80370 | The lab analyst measures the amount of or detects the presence of three or more skeletal muscle relaxants in the patient specimen. These drugs reduce the tone of skeletal muscles and thus alleviate… | 4,330 | $1 | $13K |
Showing 1–10 of 43
How this provider's Medicaid billing volume and revenue compare to other Georgia providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Georgia median
43 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 5 | 30 | 2,370 | $100 | $757.4K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 10 | 30 | 860 | $70 | $525.3K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 15 | 30 | 940 | $30 | $467.9K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 15 | 70 | 2,840 | $30 | $428.7K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 11 | 30 | 1,130 | $50 | $338.3K |
| 80332 | The lab analyst measures the amount of or detects the presence of one or two serotonergic antidepressants, which are psychiatric medications, in a patient specimen. | 4 | 10 | 730 | $10 | $23.9K |
| 80361 | The lab analyst measures the amount of or detects the presence of one or more opiates, narcotic analgesics that depress the central nervous system, in the specimen. | 2 | 10 | 690 | $1 | $22.3K |
| 80364 | The lab analyst measures the amount of or detects the presence of five or more opioids and opiate analogs, narcotic analgesics that depress the central nervous system, in the specimen. | 3 | 10 | 890 | $10 | $22.2K |
| 80357 | The lab analyst measures the amount of or detects the presence of ketamine and norketamine in the patient specimen. | 2 | 10 | 680 | $10 | $22K |
| 80346 | The lab analyst measures the amount of or detects the presence of one to twelve benzodiazepines, which are tranquilizers, in a patient specimen. | 6 | 10 | 690 | $10 | $22K |
Showing 1–10 of 43
Other providers in the same ZIP code as South Georgia Toxicology, Inc, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Hardy Gray | GA | Dentist | $0 | $2M |
| Patrick Parker | GA | Urology Physician | $783.5K | $0 |
| Gregory Martin | GA | Surgery Physician | $517K | $0 |
| Jarod Bailey | GA | Internal Medicine Physician | $373.1K | $0 |
| Charles Parramore | GA | Mental Health Counselor | $0 | $370.1K |
| Cindy Mathis | GA | Professional Counselor | $0 | $294.4K |
| Alford Brady | GA | Internal Medicine Physician | $276.9K | $0 |
| Jonathan Underwood | GA | Internal Medicine Physician | $266.4K | $0 |
| Urological Clinic Of Valdosta Ambulatory Surgical Center, LLC | GA | Ambulatory Surgical Clinic/Center | $260.7K | $0 |
| Brian Griner | GA | Pediatrics Physician | $233.8K | $8.3K |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.